Xintela appoints Sven Kili as Chief Operating OfficerLund, Sweden, 16 April 2019 - Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years' experience in the successful development and commercialization of cell and gene therapy products. "We are very fortunate that Sven Kili now has the opportunity to increase his engagement with Xintela to 50% and take on the additional role of Chief Operating Officer. We are in a very exciting, active phase, preparing for both GMP production of our stem cell product and the start of clinical studies, and Sven's deep experience in these areas will be of tremendous importance. In addition, with his great international network in cell and gene therapy, he will be key to Xintela's financing and internationalization activities," says Xintela's CEO Evy Lundgren-Åkerlund.
"I look forward to spending more time with the Xintela team and to take on more of the challenges in the company's development. Xintela has great ambition and potential with this technology and we have a very exciting journey ahead of us," says Sven Kili. 2019-04-16 Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: [email protected]
Medicon Village
223 81 Lund
www.xintela.se
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2019-04-16.pdf About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company's oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00, [email protected].
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 